Nautilus Biotechnology Inc

Nautilus Biotechnology is a development-stage life sciences company creating a single-molecule proteome analysis platform called the Voyager Platform. The company's technology uses a process called Iterative Mapping to quantify and unlock the complexity of the proteome — the full set of proteins expressed by an organism. Nautilus aims to democratize access to proteomics, enabling fundamental advancements across human health and medicine including biomarker discovery and drug target identification. The company generates early-stage revenue through grant funding (notably from The Michael J. Fox Foundation) and service revenue from its Iterative Mapping Early Access Program. Nautilus is developing a portfolio of proteoform assays spanning neurodegeneration and oncology, with plans for twenty assays through mid-2028 and instrument commercial availability targeted for mid-2027. The company is also participating in SEEDS, an ARPA-H-funded research consortium focused on Alzheimer's disease and cancer. Nautilus trades on NASDAQ under the ticker NAUT. Updated Oct 27, 2026